In:
Journal of Drug Delivery, Hindawi Limited, Vol. 2011 ( 2011-12-11), p. 1-9
Abstract:
Insulin glargine is a synthetic long-acting insulin product used for patients with diabetes mellitus. In this study, to obtain the further desirable blood-glucose lowering profile of insulin glargine, we investigated the effects of β -cyclodextrin sulfate (Sul- β -CyD) and sulfobutylether β -cyclodextrin (SBE7- β -CyD) on physicochemical properties of insulin glargine and pharmacokinetics/pharmacodynamics of insulin glargine after subcutaneous injection to rats. Sul- β -CyD and SBE7- β -CyD increased solubility of insulin glargine. SBE7- β -CyD suppressed the formation of oligomer and enhanced the dissolution rate of insulin glargine from its precipitate, compared to that of Sul- β -CyD. Additionally, we revealed that after subcutaneous administration of an insulin glargine solution, SBE7- β -CyD, but not Sul- β -CyD, increased bioavailability and sustained the blood-glucose lowering effect, possibly due to the inhibitory effects of SBE7- β -CyD on the enzymatic degradation at the injection site. These results suggest that SBE7- β -CyD could be a useful excipient for sustained release of insulin glargine.
Type of Medium:
Online Resource
ISSN:
2090-3014
,
2090-3022
Language:
English
Publisher:
Hindawi Limited
Publication Date:
2011
detail.hit.zdb_id:
2595410-6
SSG:
15,3
Permalink